Link Pharma Chem Ltd
Incorporated in 1986, Link Pharma Chem Ltd is engaged in the manufacturing and job work of organic intermediates.
- Market Cap ₹ 17.3 Cr.
- Current Price ₹ 38.9
- High / Low ₹ 50.9 / 28.2
- Stock P/E
- Book Value ₹ 28.5
- Dividend Yield 0.00 %
- ROCE -3.00 %
- ROE -7.81 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.03% over past five years.
- Company has a low return on equity of -4.49% over last 3 years.
- Debtor days have increased from 56.4 to 72.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
23.59 | 17.58 | 12.35 | 16.10 | 23.53 | 24.50 | 25.47 | 34.81 | 53.56 | 38.76 | 29.90 | 25.43 | |
21.25 | 18.36 | 12.16 | 13.56 | 20.75 | 22.48 | 22.05 | 31.67 | 50.02 | 36.04 | 30.55 | 25.30 | |
Operating Profit | 2.34 | -0.78 | 0.19 | 2.54 | 2.78 | 2.02 | 3.42 | 3.14 | 3.54 | 2.72 | -0.65 | 0.13 |
OPM % | 9.92% | -4.44% | 1.54% | 15.78% | 11.81% | 8.24% | 13.43% | 9.02% | 6.61% | 7.02% | -2.17% | 0.51% |
0.26 | 0.21 | 2.39 | -0.43 | 0.07 | 0.19 | -0.69 | -0.15 | 0.46 | -0.15 | 0.64 | 0.19 | |
Interest | 1.14 | 1.44 | 0.91 | 0.80 | 0.62 | 0.39 | 0.36 | 0.44 | 0.45 | 0.76 | 0.87 | 0.78 |
Depreciation | 0.79 | 1.13 | 0.93 | 0.83 | 0.86 | 0.89 | 0.93 | 0.87 | 0.93 | 0.92 | 1.03 | 0.94 |
Profit before tax | 0.67 | -3.14 | 0.74 | 0.48 | 1.37 | 0.93 | 1.44 | 1.68 | 2.62 | 0.89 | -1.91 | -1.40 |
Tax % | 23.88% | -29.94% | 20.27% | 54.17% | 17.52% | 29.03% | 34.03% | 35.12% | 28.24% | 26.97% | -28.80% | -26.43% |
0.52 | -2.20 | 0.59 | 0.23 | 1.13 | 0.66 | 0.95 | 1.08 | 1.88 | 0.65 | -1.36 | -1.03 | |
EPS in Rs | 1.17 | -4.95 | 1.33 | 0.52 | 2.54 | 1.49 | 2.14 | 2.43 | 4.23 | 1.46 | -3.06 | -2.32 |
Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | 0% |
3 Years: | -22% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | % |
3 Years: | % |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 26% |
3 Years: | -2% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 1% |
3 Years: | -4% |
Last Year: | -8% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
Reserves | 6.23 | 3.93 | 4.52 | 4.16 | 5.35 | 5.94 | 6.99 | 8.12 | 10.03 | 10.60 | 9.27 | 8.22 |
9.08 | 10.80 | 5.41 | 4.73 | 2.71 | 2.64 | 3.56 | 3.66 | 6.39 | 8.76 | 9.22 | 5.79 | |
6.60 | 7.35 | 3.46 | 3.81 | 4.69 | 4.99 | 3.98 | 9.82 | 8.10 | 8.66 | 3.02 | 4.84 | |
Total Liabilities | 26.35 | 26.52 | 17.83 | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 23.29 |
14.59 | 17.51 | 10.13 | 9.57 | 9.76 | 9.14 | 8.81 | 8.71 | 8.79 | 9.00 | 9.94 | 9.28 | |
CWIP | 1.92 | -0.00 | -0.00 | -0.00 | 0.01 | 0.43 | -0.00 | -0.00 | 0.21 | -0.00 | -0.00 | -0.00 |
Investments | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 4.52 | 3.64 | 2.93 | 2.06 |
9.82 | 8.99 | 7.68 | 7.54 | 7.39 | 8.41 | 10.13 | 17.30 | 15.44 | 19.82 | 13.08 | 11.95 | |
Total Assets | 26.35 | 26.52 | 17.83 | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 23.29 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.87 | 5.13 | -3.91 | 2.23 | 3.79 | 1.36 | 2.95 | 4.84 | -1.26 | -1.71 | -0.03 | 2.69 | |
-1.14 | -3.27 | 8.72 | -0.73 | -1.15 | -0.96 | -1.66 | -2.16 | -4.97 | -0.08 | 0.41 | 1.53 | |
0.30 | -0.87 | -5.75 | -1.48 | -2.63 | -0.46 | 0.55 | -0.33 | 2.27 | 1.61 | -0.41 | -4.21 | |
Net Cash Flow | 0.03 | 0.99 | -0.94 | 0.02 | -0.00 | -0.05 | 1.85 | 2.35 | -3.95 | -0.17 | -0.03 | -0.00 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 51.06 | 63.74 | 68.86 | 49.42 | 49.33 | 45.29 | 71.51 | 58.19 | 36.60 | 34.18 | 62.87 | 72.05 |
Inventory Days | 143.28 | 125.34 | 277.34 | 285.97 | 96.96 | 92.54 | 60.04 | 51.35 | 47.68 | 209.23 | 135.89 | 166.94 |
Days Payable | 110.60 | 94.59 | 81.61 | 202.93 | 124.25 | 108.98 | 110.86 | 140.70 | 45.37 | 112.90 | 38.51 | 101.21 |
Cash Conversion Cycle | 83.74 | 94.49 | 264.59 | 132.47 | 22.05 | 28.85 | 20.68 | -31.16 | 38.90 | 130.51 | 160.24 | 137.78 |
Working Capital Days | 52.14 | 39.45 | 91.32 | 75.49 | 34.59 | 41.27 | 51.45 | 15.73 | 37.96 | 90.59 | 104.74 | 92.15 |
ROCE % | 9.32% | -8.74% | -3.64% | 13.00% | 15.41% | 10.34% | 18.71% | 14.61% | 13.16% | 6.72% | -4.79% | -3.00% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 29 May
-
Non-Applicability Of Regulation 24A Of SEBI (LODR) Regulations, 2015.
27 May - Non-applicability of SEBI Regulation 24A for FY 2024-25 confirmed by Link Pharma Chem.
-
Non Applicability Of Regulations 23(9) Of SEBI (LODR) Regulations, 2015 On Disclosure Of Related Party Transactions For The Half Year Ended On 31St March, 2025.
27 May - Company exempt from SEBI related party transaction disclosure for FY ending March 2025.
-
Audited Financial Results For The Quarter And Year Ended On March 31, 2025 As Per Regulation 33 Of The SEBI (LODR) Regulations, 2015.
27 May - Audited FY25 results: Rs.140.25L loss before tax; unmodified audit opinion; routine regulatory filing.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 27Th May, 2025.
27 May - Audited FY25 results with net loss; re-appointment of secretarial, internal, and cost auditors approved.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and exports multi range intermediates for pharmaceutical, agro industries and specialty chemicals. It is also engaged in custom synthesis/contract manufacturing for multistage synthesis for small, medium, large companies.